Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Vis Exp
Main Authors: Ilié, Marius, Ngo-Mai, Mélanie, Long-Mira, Elodie, Lassalle, Sandra, Butori, Catherine, Bence, Coraline, Hamila, Marame, Hofman, Véronique, Hofman, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: MyJove Corporation 2018
Assuntos:
Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6235290/
https://ncbi.nlm.nih.gov/pubmed/30320751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3791/58082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados